English Polski
Tom 13, Nr 3 (2020)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2020-12-03

dostęp otwarty

Wyświetlenia strony 1691
Wyświetlenia/pobrania artykułu 1550
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Emicizumab (Hemlibra®) u chorych na hemofilię A powikłaną inhibitorem czynnika VIII — wytyczne Grupy ds. Hemostazy Polskiego Towarzystwa Hematologów i Transfuzjologów

Jerzy Windyga1, Krzysztof Chojnowski2, Anna Klukowska3, Paweł Łaguna3, Magdalena Łętowska4, Andrzej Mital5, Wojciech Młynarski6, Jacek Musiał7, Jacek Treliński8, Anetta Undas9, Tomasz Urasiński10, Joanna Zdziarska11, Maria Podolak-Dawidziak12
Journal of Transfusion Medicine 2020;13(3):153-164.

Streszczenie

W niniejszym artykule Grupa ds. Hemostazy Polskiego Towarzystwa Hematologów i Transfuzjologów przedstawiła zasady stosowania leku emicizumab. Emicizumab (Hemlibra ®, F. Hoffmann — La Roche, Bazylea, Szwajcaria) został dopuszczony do obrotu w krajach Unii Europejskiej w 2018 roku, a w Polsce jest dostępny dla chorych na hemofilię A powikłaną inhibitorem czynnika VIII od marca 2020 roku. Artykuł stanowi uzupełnienie wytycznych postępowania w hemofilii A i B powikłanej obecnością inhibitora czynnika VIII i IX, które ukazały się w 2017 roku.

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Windyga J, Chojnowski K, Klukowska A, et al. Część II: Wytyczne postępowania w hemofilii A i B powikłanej inhibitorem czynnika VIII i IX (2 wydanie). Acta Haematol Pol. 2017; 48(3): 137–159.
  2. Blair HA. Emicizumab: a review in Hemophilia A. Drugs. 2019; 79: 1697–1707.
  3. Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017; 117(07): 1348–1357.
  4. Lenting P, Denis C, Christophe O. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017; 130(23): 2463–2468.
  5. Hemlibra® charakterystyka produktu leczniczego. https://www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_pl.pdf.
  6. Yoneyama K, Schmitt C, Kotani N, et al. A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A. Clini Pharmacokinet. 2017; 57(9): 1123–1134.
  7. Kiialainen A, Schmitt C, Oldenburg J, et al. Pharmacokinetics and biomarkers in persons with haemophilia a (PwHA) without FVIII inhibitors receiving emicizumab once weekly in the phase 3 HAVEN 3 study [abstract no. P022] Haemophilia. 2019; 25(Suppl 1): 46–47.
  8. Kiialainen A, Schmitt C, Adamkewicz JI, et al. Pharmacokinetics and biomarkers in persons with haemophilia a (PwHA) receiving emicizumab every 2 or 4 weeks [abstract no. P021] Haemophilia. 2019; 25(Suppl 1): 45–46.
  9. Oldenburg J, Mahlangu J, Kim B, et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017; 377(9): 809–818.
  10. Young G, Liesner Ri, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019; 134(24): 2127–2138.
  11. Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018; 379(9): 811–822.
  12. Pipe S, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. The Lancet Haematology. 2019; 6(6): e295–e305.
  13. Shima M, Nogami K, Nagami S, et al. Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study). Blood. 2018; 132(Supplement 1): 1186–1186.
  14. Jimenez-Yuste V, Klamroth R, Castaman G, et al. et al.. A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of prophylactic emicizumab in persons with haemophilia A (PwHA) with FVIII inhibitors (STASEY): interim analysis results [abstract no. OC 60.3]. Res Pract Thromb Haemost. 2019; 3(Suppl 1): 116–117.
  15. Kizilocak H, Yukhtman CL, Marquez-Casas E, et al. Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays. Ther Adv Hematol. 2019; 10: 2040620719860025.
  16. Batsuli G, Zimowski KL, Tickle K, et al. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis. Haemophilia. 2019; 25(5): 789–796.
  17. Seaman C, Ragni M. Emicizumab use in major orthopedic surgery. Blood Adv. 2019; 3(11): 1722–1724.
  18. Santagostino E, Mancuso M, Novembrino C, et al. Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement. Haematologica. 2019; 104(8): e380–e382.
  19. Okamoto S, Suzuki N, Suzuki A, et al. Successful Perioperative Combination of High-Dose FVIII Therapy Followed by Emicizumab in a Patient with Hemophilia A with Inhibitors. TH Open. 2019; 3(4): e364–e366.
  20. Dargaud Y, Lienhart A, Janbain M, et al. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. Haematologica. 2018; 103(4): e181–e183.
  21. McCary I, Guelcher C, Kuhn J, et al. Real‐world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures. Haemophilia. 2020; 26(4): 631–636.
  22. Ebbert P, Xavier F, Seaman C, et al. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors. Haemophilia. 2019; 26(1): 41–46.
  23. Oldenburg J, Mahlangu JN, Bujan W, et al. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2019; 25(1): 33–44.
  24. Hartmann R, Feenstra T, Valentino L, et al. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents. J Thromb Haemost. 2018 [Epub ahead of print].
  25. Gundabolu K, Goldsweig A, Bhatt V, et al. ST‐Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII. Haemophilia. 2019; 26(1).
  26. Levy G, Asikanius E, Kuebler P, et al. Safety analysis ofrFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from theHAVENclinical program. J Thromb Haemost. 2019; 17(9): 1470–1477.
  27. Rayment R, Chalmers E, Forsyth K, et al. Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B. Br J Haematol. 2020.
  28. Paz-Priel I, Chang T, Asikanius E, et al. Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies. Blood. 2018; 132(Supplement 1): 633–633.
  29. Jenkins P, Bowyer A, Burgess C, et al. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia. 2019; 26(1): 151–155.
  30. Müller J, Pekrul I, Pötzsch B, et al. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A. Thromb Haemost. 2019; 119(09): 1384–1393.
  31. Peyvandi F, Kenet G, Pekrul I, et al. Laboratory testing in hemophilia: Impact of factor and non‐factor replacement therapy on coagulation assays. J Thromb Haemost. 2020; 18(6): 1242–1255.
  32. National Hemophilia Foundation. MASAC Document. ; 255: 2018.
  33. Collins PW, Liesner R, Makris M, et al. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia. 2018; 24(3): 344–347.
  34. Susen S, Gruel Y, Godier A, et al. Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra ): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP). Haemophilia. 2019; 25(5): 731–737.
  35. Castaman G, Santoro C, Coppola A, et al. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfus. 2020; 18(2): 143–151.



Journal of Transfusion Medicine